1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. MANKIND PHARMA LTD.
Mankind Pharma Ltd.
NSE: MANKIND | BSE: 543904

Mankind Pharma Live Share Price Today, Share Analysis and Chart

Strong Performer, Getting Expensive
BasketIn 2 Starfolio Baskets
aboutMankind Pharma Ltd. is a major player in the Indian pharmaceutical industry, ranking #4 by value and #2 by volume. Established with a focus on affordability and accessibility, the company has transitioned from a marketing-led business to a ve... Read More
US FDA InspectionsANDA Approvals
Ask AI about Mankind Pharma
2481.20-11.60(-0.47%)

29.93% Gain from 52W Low

456.2K
NSE+BSE Volume

NSE 02 Nov, 2026 3:31 PM (IST)

Portfolio

Alert

My Notes

Loading...
- / 100
- / 100
65.0 / 100
Strong Performer, Getting ExpensiveThese stocks are strong in quality and technicals but have medium valuation. At somewhat expensive valuations, investors should be cautious before buyingView SimilarEmbed DVM
Analyst Price Target
-

17

S

9

W

5

O

1

T

SWOT Analysis

Check Before You Buy

VIEW FULL CHECKLIST

High rank

15Positive8Negative

Pass in checklist65.2%

045
55
100

Check P/E Buy Sell Zone

Strong Buy Zone

11.0 %    into P/E buy sell zone

% time spent below current P/E
020406080100
Strong upside potential
Gains already realized

Mankind Pharma Stock Price Analysis

Day Price Range

-0.5% 1 Day return
2481.2 (LTP)
2,457.92,512.3
LowHigh

Week Price Range

12.1% 1 Week return
2481.2 (LTP)
2,2152,549
LowHigh

Month Price Range

-2.1% 1 Month return
2481.2 (LTP)
2,196.12,549
LowHigh

52 Week Price Range

4.1% 1 Year return
2481.2 (LTP)
1,909.72,642
LowHigh
View full Price History/Seasonality

Mankind Pharma Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Hit

Mankind Pharma's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

CURRENT EPS
46.3
AVG. ESTIMATE
58.6
LOW ESTIMATE
53.6
HIGH ESTIMATE
62
CURRENT EPS
AVG. ESTIMATE
Hit

EPS is expected to grow by 26.6% in FY27

Consensus Recommendation

18 ANALYST Recommendations
BUY

The consensus recommendation from 18 analysts for Mankind Pharma is BUY

Forecaster is a Premium Feature
You need to upgrade your subscription plan to access this feature
See what you get
Upgrade Now

Mankind Pharma Technical Analysis

Mankind Pharma EMA & SMA

Bullish+8
8 bullish, 0 bearish
Bullish8
Bearish0
5 Day2458.0
10 Day2420.8
12 Day2413.4
20 Day2401
26 Day2398.4
50 Day2399.6
100 Day2392.4
200 Day2369.8

Mankind Pharma Delivery And Volume

Daily Avg. Delivery Volume %
02 Nov, 202652.7%
Week38.8%
Month51.4%
Legend
Positive IndicatorNeutral IndicatorNegative Indicator

Mankind Pharma Resistance and Support

2483.80
Pivot
First Resistance2509.7
Second Resistance2538.2
Third Resistance2564.1
First Support2455.3
Second Support2429.4
Third Support2400.9
Day RSI57.4
Day MACD15
Day MFI54.3
Day MACD Signal Line-5.2

Mankind Pharma Beta

1 Month0.4
1 Year0.6
3 Month0.2
3 Year0.5

Mankind Pharma Price Change Analysis

↓-2.1%
Over 1 Month
LowHigh
2196.12549
↑0.5%
Over 3 Months
LowHigh
2196.12559
↑10.4%
Over 6 Months
LowHigh
2196.12642
↑4.1%
Over 1 Year
LowHigh
1909.72642
All Technicals →

Mankind Pharma Shareholding Pattern/ Ownership

Shareholding Summary

Sep 2026
 
NameCategorySharesShares %
Ramesh Juneja Family Trust (Held In The Name Of Ramesh Juneja, Managing Trustee)Promoter83,352,65220.2 %
Government Pension Fund GlobalFii4,378,8151.1 %
Nps Trust- A/C Lic Pension Fund Scheme - State GovDii10,965,3682.7 %

HISTORICAL PROMOTER HOLDING

HISTORICAL FII HOLDING

HISTORICAL MF HOLDING

All Shareholding details

Mankind Pharma Deals - Insider, Bulk, Block and SAST

Client NameDeal TypeActionDateAvg. PriceQuantityExchange
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell14 Oct 2025243055,000NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase14 Oct 2025243055,000NSE
GOLDMAN SACHS (SINGAPORE) PTE - ODIBlockSell13 Oct 2025244042,245NSE
GOLDMAN SACHS BANK EUROPE SE - ODIBlockPurchase13 Oct 2025244042,245NSE
COPTHALL MAURITIUS INVESTMENT LIMITEDBlockSell09 May 20252434.1055,000BSE
GOLDMAN SACHS (SINGAPORE) PTE.- ODIBlockPurchase09 May 20252434.1055,000BSE
COPTHALL MAURITIUS INVESTMENT LIMITEDBlockSell05 Feb 20252555.1045,000NSE
ORBIMED GENESIS MASTER FUND L.P.BlockPurchase05 Feb 20252555.1045,000NSE
HEMA CIPEF (I) LIMITEDBlockSell10 Jul 202420821,850,850NSE
HEMA CIPEF (I) LIMITEDBlockSell10 Jul 202420821,850,850NSE
All deals
All insider trades

Mankind Pharma Corporate Actions

Mankind Pharma Dividend history and yield

Mankind Pharma dividend yields, including actual and adjusted, and dividend history, including announcement, record, and ex-dividend dates. Track Mankind Pharma dividend yield over time.

#Ex-Date
Dividend AmountDividend TypeRecord DateInstrument Type
108 Aug 2025
1INTERIM08 Aug 2025Equity Share

Mankind Pharma Board Meetings

Mankind Pharma past and upcoming board meetings.

#Ex-Date
PurposeNotes
126 Oct 2026
Quarterly Results-
230 Jul 2026
Quarterly Results-
319 May 2026
Audited Results-
403 Feb 2026
Quarterly Results-
506 Nov 2025
Quarterly Results-
All Corporate Actions

Mankind Pharma Research Reports

Mankind Pharma research reports with share price targets, and buy/hold/sell recommendations from top brokers.

#
Date
Broker NameTargetPrice When RecommendedTypeUpsideChange Since RecommendationLinks
130 Jul 2026Motilal Oswal
Target
29752575.9Buy15.49%-3.68%pdf
223 Jun 2026Joindre Capital Services29782483Buy19.94%-0.07%pdf
315 Jun 2026Geojit BNP Paribas
Reco
Target
26602356.2Accumulate12.89%5.31%pdf
420 May 2026BP Wealth-2514.1Results Update--1.31%pdf
528 Apr 2026Motilal Oswal26402256.8Buy16.98%9.94%pdf
All Reports of Mankind

Mankind Pharma Corporate Filings

Mankind Pharma BSE corporate filings and AGM, press releases, insider trading & SAST, results and corporate actions.

DateAnnouncement TitleDetailsLinks
30 Oct 2026
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Please find attached transcript of the Earnings Conference Call for Q2 & H1 FY27
PDF
29 Oct 2026
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Credit Rating
Please find attached intimation regarding re-affirmation/withdrawl of Credit Rating by CRISIL
PDF
27 Oct 2026
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor Presentation
In continuation of our earlier intimation dated October 22, 2026 please find attached the Investor Presentation to be made during the said Analyst / Institutional Investors meet
PDF
27 Oct 2026
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Advertisment - Unaudited Fianncial Results of the Company for Q2 & H1 FY27
PDF
26 Oct 2026
Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Please find attached link for audio recording of the Investor Conference Call held on October 26, 2026
PDF
VIEW ALL

Mankind Pharma DocumentsAsk MarketMind AI

Mankind Pharma Earnings Call

Mankind Pharma earnings calls, including management commentary and AI-generated summaries.

DateTitleLinks
30 Oct 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
26 Oct 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
04 Aug 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
30 Jul 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeLink
26 May 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Earnings Call TranscriptLink
view all

Mankind Pharma Annual Reports

Mankind Pharma financials, including annual results, balance sheets, and cash flow statements.

DateReport TitleLinks
2026Annual Report Mar-2026Link
2026Annual Report Mar-2026Link
2025Annual Report Mar-2025Link
2024Annual Report Mar-2024Link
2023Annual Report Mar-2023Link

Mankind Pharma Credit Ratings

Mankind Pharma credit ratings from CRISIL and leading rating agencies, assessing financial stability, investment grade, and related PDF documentation.

DateRating AgencyCompany NameDescriptionLinks
28 Oct 2026crisil ratingsMankind Pharma LimitedMankind Pharma Limited:Rating reaffirmed at \u2018Crisil AA+/Stable\u2019; Commercial Paper WithdrawnLink
11 May 2026icra ratingsMankind Pharma LimitedRatings reaffirmed for existing instruments and assigned for commercial paper programmeLink
21 Apr 2026care ratingsMankind Pharma LimitedLink
23 Feb 2026icra ratingsMankind Pharma LimitedRatings reaffirmedLink
15 Jan 2026icra ratingsMankind Pharma LimitedRating withdrawn for Rs. 1,500 crore commercial paper programme; ratings outstanding for bank loan facilities and non-convertible debenture programmeLink

Mankind Pharma Investor Presentations

Mankind Pharma investor presentations, including business updates, financial insights, and strategic initiatives.

DateReport TitleLinks
26 Oct 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
30 Jul 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
19 May 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
03 Feb 2026Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor PresentationLink
06 Nov 2025Mankind Pharma Ltd - 543904 - Announcement under Regulation 30 (LODR)-Investor PresentationLink

Mankind Pharma - Company Profile

Mankind Pharma Management Structure

Mankind Pharma management structure with salaries, total experience, and qualifications.

NAMEDESIGNATIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
SHEETAL ARORAExecutive Director,Whole Time Director,Chief Executive Officer830Mar 26
Mr. Atish MajumdarSenior President(Sales & Marketing)-Mar 26
Mr. Sudipta RoySenior President(Sales & Marketing)-Mar 26
Dr. Sanjay KoulChief Marketing Officer-Mar 26
Mr. Suresh Raju PenmetsaChief Risk Officer,Senior Vice President.(EHS)-Mar 26
Mr. Prakash AgarwalPresident(Strategy)-Mar 26
Mr. Prateek DubeyGlobal Chief Human Resource Officer-Mar 26
Mr. Pankaj JainSenior Vice President(Purchase)-Mar 26
Dr. Birendra SinghSenior President(Global Quality)-Mar 26
Hitesh Kumar JainCompany Secretary,Compliance Officer-Mar 26
Dr. Anil KumarChief Scientific Officer-Mar 26
Mr. Anil GuptaVice President(Internal Audit)-Mar 26
Mr. Abhay Kumar SrivastavaSenior President(Operations)-Mar 26
Mr. Ashutosh DhawanGlobal Chief Financial Officer-Mar 26
Mr. Chanakya JunejaDirector(Technology.)-Mar 26
Mr. Arjun JunejaChief Operating Officer-Mar 26
Mr. Prem Kumar AroraDirector(FHA)-Mar 26

Mankind Pharma Board of Directors

Mankind Pharma Board of directors with salaries, total experience, and qualifications.

NAMEPOSITIONGROSS REMUNERATION ₹(LAC)AS OFHISTORY & DETAILS
RAJEEV JUNEJAVice Chairman & M.D.1957Mar 26
RAMESH CHAND JUNEJAChairman/ED & CEO1617Mar 26
SHEETAL ARORAED / WTD / CEO / Promoter830Mar 26
SATISH KUMAR SHARMAE D & Wholetime Director116Mar 26
TILOKCHAND PUNAMCHAND OSTWALIndependent Non Exe. Director57Mar 26
VIJAYA SAMPATHIndependent Non Exe. Director56Mar 26
Vivek KalraIndependent Non Exe. Director43Mar 26
Hitesh Kumar JainCompany Sec. & Compli. Officer-Mar 26
Website: www.mankindpharma.com

About the company - Business Profile

Mankind Pharma Ltd. is a major player in the Indian pharmaceutical industry, ranking #4 by value and #2 by volume. Established with a focus on affordability and accessibility, the company has transitioned from a marketing-led business to a vertically integrated organization with significant capabilities in manufacturing and R&D. It maintains a dominant presence in the domestic market, particularly in the chronic therapy and consumer healthcare segments, with over 80% market share in key categories like pregnancy test kits.

Key Points

  • Key Facts: Founded in 1991 (commenced operations in 1995), Mankind is headquartered in New Delhi. It is a listed entity on the BSE and NSE, with a market capitalization exceeding ₹1,00,000 crore (as of Dec 2025). The promoter group holds approximately 72.7% stake.
  • Operations and Resources: The company operates 30 manufacturing facilities across India (including Paonta Sahib, Haridwar, Sikkim, and Visakhapatnam) and Nepal. Its R&D infrastructure includes 6 centers staffed by over 660 scientists. Roughly 75% of its manufacturing is conducted in-house.
  • Market Significance: Mankind covers approximately 5 lakh doctors and has a distribution network of 16,000+ stockists. It is the #1 company in prescription share for the last eight years. Strategic acquisitions, such as Bharat Serums and Vaccines (BSV) and brands from Panacea Biotec, have expanded its reach into super-specialty areas like oncology and transplant medicine.
  • Business Model and Competencies: The business is built on four pillars: a steady base business, fast-growing specialty chronic, high-potential OTC (Consumer Healthcare), and the super-specialty BSV portfolio. It excels in high-volume, affordable medicine and has successfully built household brands.
  • Revenue Breakdown (FY2024-25):
    • Total Revenue: ₹12,207 crore (19% YoY growth).
    • Domestic Revenue: ₹10,675 crore (87% of total), driven by Chronic and OTC growth.
    • Export Revenue: ₹1,532 crore.
    • Therapeutic Mix: Major segments include Anti-infectives (15%), Cardiovascular (14%), Gastrointestinal (10%), Respiratory (9%), and Vitamins/Nutrients (8%).
  • Key Products and Market Share:
    • Prega News: #1 Pregnancy test kit (80% market share).
    • Manforce: #1 Condom brand (28% market share).
    • Unwanted-72: #1 Emergency contraceptive.
    • Gas-o-Fast: #2 Antacid powder (12% market share).
    • Dydroboon: First Indian company to launch in-house developed Dydrogesterone.
  • Strategic Initiatives:
    • In-licensing: Agreements with Novartis (Inclisiran), AstraZeneca (Symbicort), and Takeda (Vonoprazan) to enter premium chronic segments.
    • Acquisitions: Completed the acquisition of BSV in FY25 to bolster its biopharma and specialty portfolio.
    • Expansion: Foraying into new domains such as Agritech, Ayurveda (via Upakarma), and Pet Healthcare (Pet Star).
  • Human Resources: Employs approximately 27,000 people, with a field force of over 18,000 (as of March 2025). The company reported a 90% retention rate in its field force.

References

  1. Annual Report May 2025
  2. Investor Presentation Feb 2026
  3. Investor Presentation Nov 2025
  4. Annual Report May 2024

Mankind Pharma FAQ

Mankind Pharma today is trading in the red, down by 0.47% at ₹2,481.2.
Mankind Pharma is currently trading down 0.47% on an intraday basis. In the past week the stock rose 12.14%. Stock has been up 0.47% in the past quarter and rose 4.08% in the past year. You can view this in the share price history/seasonality section.
Mankind Pharma is listed on NSE with the ticker MANKIND and on BSE as 543904. It's currently trading on NSE at a share price of ₹2,481.2 and on BSE with a share price of ₹2,475.95.
The market cap of Mankind Pharma is ₹102,484.75 Cr. as of Nov 02, 2026.
Mankind Pharma announced a INTERIM dividend of 100% which equals ₹1 in Aug 08, 2025.To view the full dividend history of Mankind Pharma click here.
Mankind Pharma has never issued stock splits or bonus shares since the time of its listing on the BSE/NSE exchanges.
Mankind Pharma reported ₹4,432.71 Cr. in revenue, ₹711.48 Cr. in net profit, and ₹1,266.1 Cr. in EBITD as of Oct 26, 2026 for Q2 FY26-27.
According to the predictions of 19 analysts, the share price prediction for Mankind Pharma is ₹2,703.26 with an upside of 9%.
The PE ratio of Mankind Pharma is 45.7 as of Nov 02, 2026.
The PB ratio of Mankind Pharma is 6.07 as of Nov 02, 2026.
You can view the latest analyst reports on the Mankind Pharma reports dashboard. Either click on the Reports tab on this page's sub-header or click here to be directed to the dashboard.
You can set real-time stock alerts on price, volume, SMA, and several other parameters by scrolling to the top of this page and clicking the bell icon on the far right-hand side of the stock overview.
Ask AI
×